Immunovia AB (STO:IMMNOV), a manufacturer of health care devices, reported on Monday a change in the share capital and number of shares in the company due to share warrants being exercised in the company.
As a result of this, the share capital has increased by SEK6,175.00 to SEK982,742.65, while the number of shares and votes has increased by 123,500 to 19,654,853 shares and votes. Reportedly, the dilution amounts to 0.6%.
According to the company, the share warrants that have been exercised are in part constituted of Immunovia's incentive programme for senior management according to decisions taken at the 2016 AGM, issued the same year.
(EUR1.00=SEK10.75)
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system